The Power of Your Choice
Your choice of the IHTC Pharmacy Program directly supports your IHTC team and patient services, and activities provided to the hemophilia community. The IHTC Pharmacy Program provides savings to you and your health insurance plan.
Every patient has the right to choose their clotting factor pharmacy provider. The IHTC supports your right of choice and will assist you in making an informed decision.
- People with several risk factors or triggers for blood clots, such as resistance to activated protein C (APC) and an acquired condition, or those who have two inherited blood clotting disorders, are at increased risk of clots compared to people with only one risk factor. Because people with several risk factors need special consideration, it is reasonable for healthcare professionals to perform a complete evaluation on people who come to the clinic with their first or recurrent episodes of a clotting disorder. This is especially the case with children.
- APC resistance leads to a dramatically increased risk of clots associated with pregnancy or estrogen-containing oral birth control pills Because of the high frequency of APC resistance in the general population, the frequency of homozygous deficient patients may be 1:5,000.
- Warfarin (Coumadin®) should not be used during pregnancy because it may harm the growing fetus.
- Before becoming pregnant, any woman with antiphospholipid antibody syndrome who is considering pregnancy should consult a provider who specializes in high-risk pregnancies. The woman should also consult a hematologist who has knowledge of clotting disorders. Women with a history of recurrent spontaneous abortions may be placed on intravenous (IV) or subcutaneous heparin and/or oral aspirin during that time that they are trying to become pregnant or during pregnancy. This blood thinning therapy is used to prevent miscarriage caused by clotting of the blood vessels in the placenta.
In patients with heparin-induced thrombocytopenia (HIT), the platelet count should begin to recover in 2 to 5 days once all heparin is discontinued. Even after heparin therapy is stopped, however, the patient is at continued high risk of HIT-related clotting for the next 30 days. An alternate blood thinning therapy is often needed, depending on the patient’s clinical circumstances. Coumadin® therapy should not be used alone for blood thinning in people with HIT because of their high risk of developing warfarin-induced skin necrosis and gangrene in the veins of the limbs.